Back to dashboard
CommercialCoverageLow impact

08.02.04, Velmanase alfa (Lamzede)

Independence Blue Cross·Endocrinology, Pediatrics·Medical Policy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

The policy for Velmanase alfa (Lamzede) is being reissued with an effective date of May 28, 2025. This appears to be a scheduled policy update for commercial plans, though specific changes are not detailed in the summary provided.

Action Required

Action needed
By May 28, 2025: Billing team should review the full policy document at the provided URL to understand specific changes to Velmanase alfa (Lamzede) coverage and billing requirements for commercial plans. Monitor for detailed policy updates as the effective date approaches.

Related policy hubs